Caroli Christian A
Médica MIA Hospital, International Cardiovascular Medicine Clinic, Lerma, Mexico.
Clinical Council of Cardiology at Argentine Society of Cardiology, Buenos Aires, Argentina.
J Saudi Heart Assoc. 2025 Jan 30;37(1):8. doi: 10.37616/2212-5043.1416. eCollection 2025.
The new 2024 European guideline on chronic coronary syndromes (CCS) is a pivotal document for clinical practice, updating the evidence and indications after five years, incorporating insights from the paradigm-shifting ISCHEMIA trial. This article explores the evolving role of functional and anatomical testing in assessing coronary artery disease (CAD), highlighting the introduction of a new risk probability score based on clinical and risk factors. Additionally, it provides a detailed comparison between these European recommendations and those from the most influential American guidelines, emphasizing key differences in the approach to risk stratification and diagnostic strategies. This comprehensive analysis provides valuable insights for optimizing the management of a syndrome that, in light of new evidence, has proven to be clinically complex and, in many aspects, counterintuitive.
新的2024年欧洲慢性冠状动脉综合征(CCS)指南是临床实践的关键文件,在五年后更新了证据和适应症,并纳入了具有范式转变意义的ISCHEMIA试验的见解。本文探讨了功能和解剖学检测在评估冠状动脉疾病(CAD)中不断演变的作用,重点介绍了基于临床和风险因素的新风险概率评分的引入。此外,它还对这些欧洲建议与最具影响力的美国指南进行了详细比较,强调了风险分层方法和诊断策略的关键差异。这一全面分析为优化该综合征的管理提供了宝贵见解,鉴于新证据,该综合征在临床上已被证明是复杂的,且在许多方面有悖直觉。